T-lymphoblastic Lymphoma/Leukaemia Terminated Phase 2 Trials for Isatuximab (DB14811)

IndicationStatusPhase
DBCOND0125599 (T-lymphoblastic Lymphoma/Leukaemia)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02999633Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaTreatment